We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Differential Biochemical Markers Identified in Inflammatory Processed Synovial Fluid

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: The AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures many different chemical analytes (Photo courtesy of Beckman Coulter)
Image: The AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures many different chemical analytes (Photo courtesy of Beckman Coulter)
Joint infections with a non-specific presentation are difficult to diagnose, mainly due to the absence of specific clinical signs and symptoms, relative lack of accurate laboratory tests, low virulence due to previous treatment, and biofilm ability of the pathogens.

This difficulty is especially true for patients treated with non-targeted antibiotics, including patients with implanted joint replacements. New biochemical markers are being sought to help quickly determine the extent of the inflammatory process taking place in the joint cavity in routine biochemical practice, either due to its increased concentration in synovial fluid (SF) or directly in serum/plasma.

Clinical Biochemists and their colleagues at the University of Ostrava (Ostrava, Czech Republic) sought to identify biochemical markers in Synovial Fluid (SF) that can predict susceptibility to ongoing inflammatory processes in the joint cavity. Ninety-two consecutive patients were divided into four SF groups based on clustering analysis: non-inflammatory SF (73%), inflammatory-non-pyogenic (12%), inflammatory-pyogenic (10%), or hemorrhagic (5%).

The team measured and compared the levels of the following biochemical markers in SF: glucose, lactate, total protein, uric acid, C-Reactive Protein (CRP), Leukocyte Count (WBC), Mononuclear (MNP), Polymorphonuclear (PMN), Interleukin (IL)-1 beta, IL6, Procalcitonin, Presepsin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Human Neutrophil Defensin 1-3 (HNP1-3), Cartilage Oligomeric Matrix Protein, Lactoferrin (HLF2), Polymorphonuclear Elastase (PMNE), Matrix Metalloproteinase (MMP)-1, and MMP-3. The concentrations of the biochemical biomarkers were determined on an AU 5800 automated analyzer (Beckman Coulter, Brea, CA, USA). They analyzed hematological parameters, relative and absolute numbers of leukocytes (WBC), and (MNP) and PMN leukocyte counts on a XN-9000 Automated in Body Fluid mode (Sysmex, Kobe, Japan).

The scientists reported that a significant difference between WBC, PMN, MNP, CRP, IL-1β, IL-6, HNP1-3, HLF2, PMNE, and individual groups of SF type. They also found a significant correlation between WBC and PMN, MNP, and CRP; PMN and HNP1-3 and PMNE; IL-6 and PMNE; IL-1β and NGAL, HLF2, and PMNE; HNP1-3 and NGAL, HLF2, and PMNE; NGAL and HLF2 and PMNE; and HLF2 and PMNE concentrations in all SF groups, between WBC and MNP; IL-1β and NGAL and MMP-3; HNP1-3 and PMNE; and NGAL and HLF2 concentrations in the non-inflammatory SF group, and between PMN and MNP in the inflammatory-non-pyogenic and inflammatory-pyogenic SF groups. PMN, MNP, WBC, CRP, and HNP1-3 in SF predicted the inflammatory processes with excellent diagnostic performance.

The authors concluded that SF biomarkers WBC, PMN, MNP CRP, HNP1-3, IL-1, IL-6, PMNE, and HLF2 allow the classification of new patients into the relevant SF group with an accuracy of 94.4%. In addition, WBC, PMN, MNP, CRP, and HNP1-3 provide excellent diagnostic sensitivity and specificity for the diagnosis of infection, despite the study including a limited number of patients with pyogenic and non-pyogenic inflammation. The study was originally published on line on March 15, 2021 in the Journal of Clinical Chemistry and Laboratory Medicine.

Related Links:
University of Ostrava
Beckman Coulter
Sysmex


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.